Barclays
RANI icon

Barclays’s Rani Therapeutics RANI Stock Holding History

Barclays’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$8.29K Buy
10,486
+450
+4% +$359 ﹤0.01% 4854
2026
Q2 		$7.63K Sell
10,036
-210
-2% -$186 ﹤0.01% 4732
2026
Q1 		$7.53K Buy
10,246
+2,150
+27% +$2.75K ﹤0.01% 4735
2025
Q4 		$10.9K Buy
+8,096
New +$12.2K ﹤0.01% 4926
2024
Q2 		– Sell
-39
Closed -$121 – 5215
2024
Q1 		$121 Buy
+39
New +$134 ﹤0.01% 4993

Other funds holding RANI

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Kestra Private Wealth Services
Kestra Private Wealth Services Austin, Texas $9.37B AUM 22.72% 1-Year Est. Return
CWA Asset Management Group
CWA Asset Management Group Naples, Florida $3.39B AUM 25.16% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Luther King Capital Management (LKCM)
Luther King Capital Management (LKCM) Fort Worth, Texas $24.3B AUM 19.37% 1-Year Est. Return
Well Done LLC
Well Done LLC Holland, Michigan $732M AUM 14.62% 1-Year Est. Return
Traphagen Investment Advisors
Traphagen Investment Advisors Oradell, New Jersey $1.46B AUM 14.92% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
ACT Advisors
ACT Advisors Asheville, North Carolina $308M AUM 16.31% 1-Year Est. Return

Barclays's RANI Position: Q3 2026 in Review

Barclays increased its Rani Therapeutics (RANI) stake by 4.5% in Q3 2026, buying an estimated $359 and bringing the position to 10,486 shares worth $8.29K. The position accounts for ﹤0.01% of the portfolio, ranked #4854.

Barclays first reported a position in RANI in Q1 2024 and has held it in 5 quarters since. The position peaked at $10.9K in Q4 2025. 20 funds tracked by Wall St. Rank hold RANI as of Q3 2026.

  • Barclays held 10,486 shares of Rani Therapeutics worth $8.29K as of Q3 2026.
  • Barclays bought 450 Rani Therapeutics shares in Q3 2026, an estimated $359.
  • Rani Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4854 holding.
  • Barclays first reported a position in Rani Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • Barclays's Rani Therapeutics position peaked at $10.9K in Q4 2025.
  • 20 funds tracked by Wall St. Rank held Rani Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.